Blog

Artificial Intelligence for Drug & Biological Products – Credibility of AI Models for Context of Use – The “Model Risk” Paradigm

The FDA has recently issued draft guidance (non-binding recommendations) for drug and biological product sponsors and computer programmers regarding the use of Machine Learning (ML) and artificial intelligence (AI) to support regulatory decision-making about the safety, effectiveness, or quality of drugs.

read more